Dobrzycka Bożena, Terlikowski Sławomir J
Department of Obstetrics, Gynecology and Obstetrics/Gynecological Care, Medical University of Bialystok, Poland.
Folia Histochem Cytobiol. 2010 Sep 30;48(3):319-22. doi: 10.2478/v10042-10-0061-8.
Endometrial cancer is the most common gynecologic malignancy in more developed countries. Approximately 75% of cases are diagnosed at an early stage with a tumor confined to the uterine corpus. Although most patients are cured by surgery alone, about 15-20% with no signs of locally advanced or metastatic disease at primary treatment recurs, with limited responsiveness to systemic therapy. The most common basis for determining the risk of recurrent disease has been classification of endometrial cancers into two subtypes. Type I, associated with a good prognosis and endometrioid histology and type II, associated with a poor prognosis and non-endometrioid histology. This review will focus primarily on the molecular biomarkers that have supported the dualistic model of endometrial carcinoma and help determine which patients would benefit from either adjuvant therapy or more aggressive primary treatment.
子宫内膜癌是较发达国家最常见的妇科恶性肿瘤。约75%的病例在早期被诊断出来，肿瘤局限于子宫体。虽然大多数患者仅通过手术就能治愈，但约15%-20%在初始治疗时无局部晚期或转移性疾病迹象的患者会复发，对全身治疗的反应有限。确定疾病复发风险最常见的依据是将子宫内膜癌分为两种亚型。I型与预后良好和子宫内膜样组织学相关，II型与预后不良和非子宫内膜样组织学相关。本综述将主要关注支持子宫内膜癌二元模型的分子生物标志物，并帮助确定哪些患者将从辅助治疗或更积极的初始治疗中获益。
